Nuwellis, Inc. (NUWE)
NASDAQ: NUWE · Real-Time Price · USD
0.2580
+0.0029 (1.14%)
At close: Jun 26, 2025, 4:00 PM
0.2550
-0.0030 (-1.16%)
After-hours: Jun 26, 2025, 7:55 PM EDT

Company Description

Nuwellis, Inc., a medical device company, develops, manufactures, and commercializes medical devices used in ultrafiltration therapy.

The company offers Aquadex FlexFlow and Aquadex SmartFlow systems, which are used to treat patients suffering from fluid overload due to heart failure.

Its Aquadex FlexFlow system includes a console, disposable blood circuit set, and disposable catheter.

The company sells its products to hospitals and clinics through its direct salesforce in the United States; and through specialty healthcare distributors in Austria, Belarus, Brazil, Colombia, the Czech Republic, Germany, Greece, Hong Kong, India, Indonesia, Israel, Italy, Panama, Romania, Singapore, Slovak Republic, Spain, Switzerland, Thailand, the United Arab Emirates, and the United Kingdom.

The company was formerly known as CHF Solutions, Inc. and changed its name to Nuwellis, Inc. in April 2021.

Nuwellis, Inc. was founded in 1999 and is headquartered in Eden Prairie, Minnesota.

Nuwellis, Inc.
Nuwellis logo
Country United States
Founded 1999
Industry Medical Devices
Sector Healthcare
Employees 38
CEO John Erb

Contact Details

Address:
12988 Valley View Road
Eden Prairie, Minnesota 55344
United States
Phone 952 345 4200
Website nuwellis.com

Stock Details

Ticker Symbol NUWE
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001506492
CUSIP Number 12542Q706
ISIN Number US67113Y6032
Employer ID 68-0533453
SIC Code 3845

Key Executives

Name Position
John L. Erb Interim President, Interim Chief Executive Officer and Chairman of the Board
Robert B. Scott Chief Financial Officer
Neil P. Ayotte Esq. Senior Vice President, General Counsel, Secretary and Chief Compliance Officer
Kim Anderson Vice President of Operations
Betsy Riemenschneider Vice President of Sales
Dr. John Lynn Jefferies FACC, M.B.A., M.D., M.P.H. Chief Medical Officer and Member of Medical Advisory Board
Paul Wotta Corporate Controller

Latest SEC Filings

Date Type Title
Jun 23, 2025 8-K Current Report
Jun 16, 2025 SCHEDULE 13D Filing
Jun 13, 2025 SCHEDULE 13G Filing
Jun 12, 2025 SCHEDULE 13G Filing
Jun 10, 2025 424B4 Prospectus
Jun 9, 2025 EFFECT Notice of Effectiveness
Jun 9, 2025 8-K Current Report
Jun 3, 2025 S-1/A [Amend] General form for registration of securities under the Securities Act of 1933
May 30, 2025 S-1 General form for registration of securities under the Securities Act of 1933
May 29, 2025 SD Form - SD